The COVID-19 pandemic has been met with an unprecedented response from the scientific
community, leading to the development, investigation, and authorization of vaccines and …

The Omicron (B. 1.1. 529) variant of the severe acute respiratory syndrome Coronavirus 2
(SARS-CoV-2) had an increased rate of spreading among the general population. Although …

During the last three and a half years (2020-2023), the coronavirus disease 2019 (COVID-
19), caused 87 by the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) …

The SARS-CoV-2 (severe acute respiratory syndrome coronavirus responsible for the
COVID-19 disease) uses the Spike proteins of its envelope for infecting target cells …

Background Since the beginning of the COVID-19 pandemic, therapeutic options for treating
COVID-19 have been investigated at different stages of clinical manifestations. Considering …

Summary Background NVX-CoV2373, a Covid-19 vaccine was developed in the USA with∼
90% efficacy. The same vaccine is manufactured in India after technology transfer (called as …

Due to waning immunity following primary immunization with COVID-19 vaccines, booster
doses may be required. The present study assessed a heterologous booster of SII-NVX …

After three years and a half since the pandemic due to the Severe Acute Respiratory
Syndrome coronavirus 2 (SARS-CoV-2) causing Coronavirus Disease 2019 (COVID-19) …

Background The COVID-19 pandemic has evolved quickly, with different variants of concern
resulting in the need to offer continued protection through booster vaccinations. The duration …

Abstract Acute Disseminated Encephalomyelitis (ADEM) and Transverse Myelitis (TM) are
within the group of immune mediated disorders of acquired demyelinating syndromes. Both …